A tailored course, built for your situation
Advanced Neuroendocrine Tumor Management: Clinical Strategy & Implementation
A 12-module mastery program for clinicians leading complex neuroendocrine tumor cases with precision and confidence
$199 one-time
24-hour access provisioning
30-day money-back guarantee
Hand-built implementation playbook
12 modules. 12 chapters per module. 144 chapters total.
12 modules, each with 12 chapters (144 chapters total), text-based, plus downloadable templates and a hand-built implementation playbook delivered alongside course access.
Staying ahead of evolving treatment protocols while managing complex patient outcomes can feel overwhelming, even for experienced oncologists.
The situation this course is for
The field of neuroendocrine tumor management is advancing rapidly, with new therapeutic agents and combination strategies emerging frequently. Clinicians face increasing pressure to integrate current evidence, manage side effects proactively, and align treatment plans with multidisciplinary teams, all while maintaining clarity in decision-making. Without a structured framework, it's easy to miss key updates or delay optimal interventions.
Who this is for
A practicing medical oncologist or endocrinologist with experience in neuroendocrine tumors, actively managing patient care and staying current with clinical trials and guideline changes.
Who this is not for
This course is not for students, general internists without subspecialty exposure, or non-clinical professionals. It assumes prior experience in oncology and familiarity with targeted therapies.
What you walk away with
- Apply the latest evidence-based protocols for everolimus and sunitinib in advanced NETs
- Design individualized treatment pathways using biomarker and imaging data
- Integrate proteasome inhibitors into trial-informed care strategies
- Lead multidisciplinary discussions with confidence in drug selection and sequencing
- Implement a structured follow-up system to track response and toxicity
The 12 modules (with all 144 chapters)
Module 1. Evolving Landscape of Neuroendocrine Tumor Therapy
Explore current trends shaping clinical decisions in neuroendocrine tumors, including guideline updates, real-world evidence adoption, and shifts in treatment sequencing.
12 chapters in this module
- Defining advanced neuroendocrine tumors
- Historical treatment benchmarks
- Current standard-of-care pathways
- Emerging agent categories
- Guideline organization roles
- Trial-to-practice translation lag
- Global access variations
- Multidisciplinary team structure
- Patient stratification models
- Biomarker integration status
- Imaging evolution impact
- Therapeutic escalation triggers
Module 2. mTOR Inhibition with Everolimus
Master the mechanism, patient selection, dosing, and monitoring strategies for everolimus in pancreatic and non-pancreatic NETs based on pivotal trials and real-world use.
12 chapters in this module
- mTOR pathway biology
- Everolimus mechanism of action
- Pancreatic NET trial data
- Extrapancreatic NET outcomes
- Dosing initiation standards
- Dose titration protocols
- Common side effect profiles
- Stomatitis management steps
- Hematologic monitoring schedule
- Renal function tracking
- Drug interaction checklist
- Discontinuation criteria
Module 3. Tyrosine Kinase Inhibition Using Sunitinib
Understand the role of sunitinib in progressive pancreatic NETs, including sequencing, toxicity management, and integration with imaging response criteria.
12 chapters in this module
- VEGF pathway relevance
- Sunitinib molecular target
- Progression-free survival data
- Patient eligibility markers
- Initiation timing options
- Dose scheduling formats
- Hand-foot syndrome response
- Hypertension monitoring
- Thyroid function changes
- Imaging interpretation shifts
- Combination therapy risks
- Treatment holiday planning
Module 4. Proteasome Inhibitors in Neuroendocrine Context
Evaluate the evidence for bortezomib and related agents in neuroendocrine tumors, including trial design limitations and biomarker-driven response prediction.
12 chapters in this module
- Proteasome function overview
- Bortezomib mechanism
- Phase II trial structure
- Response rate outcomes
- Toxicity profile summary
- Neuropathy management
- Hematologic risk factors
- Dosing schedule variants
- Combination rationale
- Patient selection criteria
- Biomarker correlation status
- Future trial directions
Module 5. Biomarker-Driven Treatment Selection
Leverage chromogranin A, NSE, and genetic markers to guide therapy initiation, escalation, and response assessment across multiple lines of care.
12 chapters in this module
- Chromogranin A reliability
- Neuron-specific enolase role
- Genetic mutation screening
- MEN1 status implications
- DAXX/ATRX testing access
- Circulating tumor DNA use
- Grade vs marker alignment
- Baseline biomarker panel
- Serial monitoring schedule
- Interference factors list
- False elevation causes
- Reporting standardization
Module 6. Imaging for Response Assessment
Apply RECIST and alternative criteria to CT, MRI, and functional imaging to accurately assess tumor response and guide clinical decisions.
12 chapters in this module
- RECIST 1.1 applicability
- Modified RECIST use
- CT scan timing protocol
- MRI advantage scenarios
- Somatostatin receptor imaging
- Ga-68 DOTATATE utility
- PET-CT interpretation
- Tumor density changes
- Necrosis vs progression
- Pseudoprogression recognition
- Volume-based tracking
- Reporting template use
Module 7. Sequencing First, Second, and Later-Line Therapies
Develop a logical, evidence-informed sequence for mTOR inhibitors, TKIs, chemotherapy, and peptide receptor radionuclide therapy.
12 chapters in this module
- First-line decision drivers
- Everolimus positioning
- Sunitinib sequencing
- PRRT integration timing
- Streptozocin use cases
- Capecitabine combination
- Clinical trial access points
- Progression definition
- Second-line initiation
- Third-line options
- Rechallenge considerations
- End-of-life planning
Module 8. Managing Adverse Events and Treatment Continuity
Implement proactive monitoring and intervention strategies to reduce discontinuation rates and maintain dose intensity.
12 chapters in this module
- Toxicity grading systems
- Dose reduction algorithm
- Stomatitis care protocol
- Hypertension management
- Fatigue assessment tool
- Hypothyroidism screening
- Hematologic support plan
- Infection risk mitigation
- Dermatologic side effects
- GI symptom tracking
- Renal monitoring schedule
- Treatment pause criteria
Module 9. Multidisciplinary Coordination in Complex Cases
Lead tumor boards and care teams with structured communication tools that align oncology, surgery, radiology, and nuclear medicine.
12 chapters in this module
- Tumor board frequency
- Case presentation format
- Surgical referral triggers
- Liver-directed therapy options
- Radiologist collaboration
- Nuclear medicine input
- Endocrinology consultation
- Pathology integration
- Genetics counseling access
- Palliative care timing
- Social work involvement
- Caregiver communication
Module 10. Clinical Trial Navigation and Patient Enrollment
Identify appropriate trials, evaluate eligibility, and guide patients through informed consent and participation logistics.
12 chapters in this module
- Trial identification sources
- Eligibility checklist
- Informed consent process
- Institutional review board
- Sponsor contact steps
- Patient motivation factors
- Travel logistics planning
- Monitoring requirements
- Data sharing policies
- Withdrawal procedures
- Post-trial access options
- Real-world data contribution
Module 11. Patient Communication and Shared Decision-Making
Build clear, empathetic frameworks for discussing prognosis, treatment options, and quality-of-life trade-offs.
12 chapters in this module
- Prognosis discussion timing
- Survival statistic framing
- Treatment goal alignment
- Option grid use
- Risk-benefit visualization
- Quality-of-life assessment
- Caregiver inclusion
- Cultural sensitivity
- Health literacy adaptation
- Decision regret reduction
- Follow-up expectation setting
- Advance directive review
Module 12. Implementation and Long-Term Practice Integration
Deploy a personalized system for maintaining protocol accuracy, updating team knowledge, and tracking patient outcomes over time.
12 chapters in this module
- Guideline update tracking
- Internal audit schedule
- Team training protocol
- Protocol checklist creation
- Electronic health record templates
- Patient education materials
- Outcome dashboard setup
- Benchmark comparison
- Peer review submission
- Conference preparation
- Publication opportunity spotting
- Leadership role development
How this maps to your situation
- Managing a newly diagnosed advanced NET case
- Deciding between everolimus and sunitinib in a progressing patient
- Coordinating care during bortezomib trial participation
- Leading a tumor board with conflicting expert opinions
Before vs. after
Before
Overwhelmed by the pace of change in neuroendocrine tumor therapy, juggling multiple guidelines and trial data without a clear system.
After
Confidently leading patient care with a structured, up-to-date framework that integrates biomarkers, imaging, and multidisciplinary input.
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 3 hours per module, designed for flexible, self-paced learning with immediate clinical applicability.
If nothing changes
Without a current, integrated approach, there's a growing chance of suboptimal treatment sequencing, missed trial opportunities, and reduced patient outcomes due to outdated or fragmented decision-making.
How this compares to the alternatives
Unlike general oncology reviews or passive webinar series, this course delivers structured, action-oriented guidance with direct implementation tools tailored to neuroendocrine tumor management, no generic content or outdated protocols.
Frequently asked
Is this course focused on pancreatic or extrapancreatic NETs?
It covers both, with dedicated sections on site-specific decision-making and biomarker use.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Are the materials updated as new evidence emerges?
The core curriculum is current as of the latest published guidelines, with a built-in update tracking system included in Module 12.
$199 one-time. Approximately 3 hours per module, designed for flexible, self-paced learning with immediate clinical applicability..
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.
30-day money-back guarantee·
144 chapters·
Hand-built playbook included·
Account access within 24 hours